Clinical Trials Logo

Clinical Trial Summary

Background: Smith-Lemli-Opitz Syndrome (SLOS) is a genetic disorder. It can cause birth defects and developmental delays. There is no cure for SLOS or other inherited diseases related to cholesterol production or storage. The data gained in this study may help researchers find ways to measure how well future treatments work. Objective: To learn more about SLOS and related disorders and how these diseases affect participants and relatives. Eligibility: People of any age who have or are suspected to have SLOS or another inherited disease related to cholesterol production or storage. Relatives are also needed. Design: Participants will be screened with a medical record review. Participants will have visits every 6 to 12 months. They will have a physical exam. They will fill out a survey about their medical and behavioral history. They may have an eye exam. They may have a neurodevelopmental assessment. They may have a hearing test. Their outer and middle ears may be examined. Their ability to speak, understand speech, eat, and swallow may be assessed. They may get X-rays while they chew and swallow. Their functional ability and needs for adaptive devices or braces may be assessed. They may have a lumbar puncture. Photographs may be taken of their face and body. Participants who cannot visit the NIH and relatives will have a virtual visit once a year. They will talk about their medical history and symptoms. They give blood, urine, and skin samples at a lab near their home. They will fill out a survey about their medical and behavioral history. Participation will last for several years.


Clinical Trial Description

Study Description: The objective of this study is to characterize the natural history of Smith-Lemli-Opitz Syndrome (SLOS) and related disorders (such as lathosterolosis, desmosterolosis, X-linked dominant chondrodysplasia punctata (CDPX2), CHILD syndrome, HEM dysplasia, and Antley-Bixler syndrome) by collecting both crosssectional and longitudinal data on individuals with these conditions. Our goal is to investigate genetic, biochemical, and clinical aspects of SLOS and related disorders in order to facilitate development and implementation of future therapeutic trials. This protocol consists of a main study and two substudies. The main study involves in-person evaluation of patients and carriers of SLOS and related disorders. The first substudy includes collecting biorepository samples from patients and carriers of SLOS and related disorders. The second substudy involves obtaining a telemedicine history and full review of systems for patients with SLOS and related disorders. This protocol will also maintain a database of information collected over the past two decades at the NIH on SLOS trial participants. All individuals with SLOS, related disorders and carriers will be eligible for enrollment. Objectives: The primary objective of this study is to determine laboratory or clinical outcome measures that could be used in future therapeutic trials. The secondary objectives of these studies are to define comorbidities and mortality of the disease, to identify potential participants for future therapeutic trials and to evaluate possible laboratory outcome measures in carriers and suspected carriers. Endpoints: Primary endpoints 1. Phenotypic characterization of individuals with SLOS and related inborn errors of cholesterol synthesis. Define and characterize disease related morbidity and mortality. 2. Establishing a biomaterial collection (Blood, urine, CSF, DNA/RNA and cell lines) corresponding to well-phenotyped individuals for biomarker discovery and characterization. Secondary endpoints: Phenotypic history as well as blood and urine biomarkers in individuals heterozygous for pathogenic DHCR7 variants or pathogenic variants in cholesterol synthetic genes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05047354
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact Samar N Rahhal, M.D.
Phone (202) 468-1716
Email rahhalsn@nih.gov
Status Recruiting
Phase
Start date June 23, 2021
Completion date May 31, 2031

See also
  Status Clinical Trial Phase
Withdrawn NCT01110642 - Novel Treatment for Syndromic Ichthyoses Phase 2
Completed NCT02383316 - Study of Metabolic Modifications in Children With Noonan Syndrome N/A
Completed NCT05131542 - Assessment of Hypotonia in Children With Down Syndrome